fig1
From: PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Figure 1. Correlation of platinum sensitivity with response to olaparib (AZD2281) in BRCA-mutated ovarian cancer, taken from the presentation by Fong et al.[14] in the ASCO 2008 Annual Meeting. Longer complete and partial responses (CR/PR light green), and stable disease (SD, dark green), were seen in platinum-sensitive ovarian cancer, but also in some platinum-resistant and a brief signal in platinum- refractory ovarian cancer
